Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up.

Infection·2024
Same author

[Interdisciplinary ultrasound-guided, minimally invasive autopsy in COVID-19-deceased patients in the intensive care unit of a university hospital : A proof-of-concept study].

Pathologie (Heidelberg, Germany)·2023
Same author

Rapid point-of-care detection of SARS-CoV-2 infection in exhaled breath using ion mobility spectrometry: a pilot study.

European journal of medical research·2023
Same author

Multidimensional Analysis of the Mother-to-child Transmission Risk Factors in Chronic Hepatitis B Virus Infection in Pregnant Women in Vietnam.

La Clinica terapeutica·2023
Same author

[Strategietreffen: Virushepatitis in Deutschland eliminieren].

Zeitschrift fur Gastroenterologie·2023
Same author

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.

Blood·2022

Related Experiment Video

Updated: Jun 5, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Can engineered "designer" T cells outsmart chronic hepatitis B?

U Protzer1, H Abken

  • 1Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, 81675 München, Germany.

Hepatitis Research and Treatment
|December 29, 2010
PubMed
Summary

Persistent human hepatitis B virus (HBV) infection affects millions globally, risking liver disease. Genetically engineered T cells show promise for eliminating infected cells, offering a new therapeutic avenue beyond current treatments.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jun 5, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Over 350 million people worldwide suffer from chronic hepatitis B virus (HBV) infection.
  • HBV infection significantly increases the risk of developing severe liver conditions like cirrhosis and hepatocellular carcinoma.
  • Current treatments, including vaccines and antivirals, face challenges in eliminating persistently infected cells.

Purpose of the Study:

  • To explore novel immunotherapeutic strategies for eliminating HBV-infected cells.
  • To investigate the potential of adoptive cell therapy in managing chronic HBV infection.
  • To assess the efficacy of genetically engineered T cells in targeting and clearing HBV-infected hepatocytes.

Main Methods:

  • Experimental investigation of adoptive cell therapy.
  • Utilizing genetically engineered "designer" T cells.
  • Focusing on an immunotherapeutic approach to target HBV-infected cells.

Main Results:

  • Preliminary exploration of T cell-based immunotherapy for HBV.
  • Demonstration of a biological attack strategy against infected cells.
  • Potential for engineered T cells to eliminate HBV-infected cells.

Conclusions:

  • Adoptive cell therapy with engineered T cells is a promising experimental approach for HBV.
  • Targeting HBV-infected cells via immunotherapy offers a potential solution for persistent infections.
  • Further research is warranted to develop this approach into a viable treatment for chronic hepatitis B.